CME GROUP INC (CME) Stock Analyst Ratings
USA - NASDAQ:CME - US12572Q1058 - Common Stock
279.58 USD
+0.74 (+0.27%)
279.58 USD
0 (0%)
ChartMill assigns a Buy % Consensus number of 73% to CME. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 290.51. This target is 3.91% above the current price.
CME was analyzed by 22 analysts. The buy percentage consensus is at 73. So analysts seem to be have mildly positive about CME.
In the previous month the buy percentage consensus was at a similar level.
CME was analyzed by 22 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-10-23 | UBS | Maintains | Neutral -> Neutral |
| 2025-10-23 | Deutsche Bank | Upgrade | Hold -> Buy |
| 2025-10-23 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2025-10-13 | Raymond James | Maintains | Outperform -> Outperform |
| 2025-10-08 | Barclays | Maintains | Equal-Weight -> Equal-Weight |
| 2025-10-01 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2025-09-25 | JP Morgan | Maintains | Underweight -> Underweight |
| 2025-09-25 | Citigroup | Upgrade | Neutral -> Buy |
| 2025-09-08 | UBS | Maintains | Neutral -> Neutral |
| 2025-07-24 | UBS | Downgrade | Buy -> Neutral |
| 2025-07-24 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2025-07-24 | Barclays | Maintains | Equal-Weight -> Equal-Weight |
| 2025-07-15 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2025-07-10 | Barclays | Maintains | Equal-Weight -> Equal-Weight |
| 2025-07-03 | Citigroup | Maintains | Neutral -> Neutral |
| 2025-06-04 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2025-04-25 | UBS | Maintains | Buy -> Buy |
| 2025-04-24 | Keefe, Bruyette & Woods | Maintains | Market Perform -> Market Perform |
| 2025-04-24 | JP Morgan | Maintains | Underweight -> Underweight |
| 2025-04-24 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2025-04-23 | Barclays | Maintains | Equal-Weight -> Equal-Weight |
| 2025-04-11 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2025-04-08 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2025-04-07 | Barclays | Maintains | Equal-Weight -> Equal-Weight |
| 2025-04-03 | RBC Capital | Reiterate | Sector Perform -> Sector Perform |
| 2025-04-02 | B of A Securities | Maintains | Underperform -> Underperform |
| 2025-03-10 | Raymond James | Upgrade | Market Perform -> Outperform |
| 2025-02-19 | Morgan Stanley | Maintains | Equal-Weight -> Equal-Weight |
| 2025-02-14 | Keefe, Bruyette & Woods | Maintains | Market Perform -> Market Perform |
| 2025-02-13 | Oppenheimer | Maintains | Outperform -> Outperform |
CME GROUP INC / CME FAQ
What is the average price target for CME GROUP INC (CME) stock?
22 analysts have analysed CME and the average price target is 290.51 USD. This implies a price increase of 3.91% is expected in the next year compared to the current price of 279.58.
Can you provide the consensus rating for CME GROUP INC stock?
The consensus rating for CME GROUP INC (CME) is 72.7273 / 100 . This indicates that analysts generally have a positive outlook on the stock.
How many analysts have analysed CME GROUP INC (CME)?
The number of analysts covering CME GROUP INC (CME) is 22.